MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202517045652 A) filed by Corcept Therapeutics Incorporated, Redwood City, U.S.A., on May 12, for 'treatments for amyotrophic lateral sclerosis using dazucorilant.'
Inventor(s) include Mann Grace; Tudor Iulia Cristina; Guyer William; Hunt Hazel; and Custodio Joseph.
The application for the patent was published on May 30, under issue no. 22/2025.
According to the abstract released by the Intellectual Property India: "Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments the heteroaryl ketone fused azadecalin compound is dazucorilant: (R) (1 (4 fluorophenyl) 6 ((4 (trifluoromethyl)phenyl) sulfonyl) 4 4a 5 6 7 8 hexahydro 1 H pyrazolo[3 4 g]isoquinolin 4a yl) (pyridin 2 yl)methanone having the chemical structure illustrated as. Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food or with water or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2 fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration enteral administration or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include e.g. pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration."
The patent application was internationally filed on Oct. 27, 2023, under International application No.PCT/US2023/078018.
Disclaimer: Curated by HT Syndication.
